*ST赛隆(002898.SZ)：右兰索拉唑获得化学原料药上市申请批准通知书

Core Viewpoint - *ST Sailong (002898.SZ) has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Rabeprazole, which is indicated for the treatment of bleeding gastric ulcers and duodenal ulcers when oral therapy is not suitable [1] Group 1 - The approval pertains to the injection formulation of Rabeprazole [1] - The drug is specifically aimed at treating conditions that cannot be managed with oral therapies [1]